YAP1 and cancer: Equally promising is the combination with YAP-TAZ-TEAD pathway inhibitors, as nuclear PYK2 scaffolds transcriptional complexes (e.g., PYK2-Src-YAP/TAZ) critical for cancer stemness maintenance and EMT in PDAC and other GI malignancies (18, 25, 34).